Business Context and Reporting Period
Company: EyePoint Pharmaceuticals, Inc. (EYPT)
Filing Type: Form 8-K (Current Report)
Date of Report: May 17, 2023
Event: Entry into a Material Definitive Agreement and Termination of a Material Definitive Agreement.
On May 17, 2023, EyePoint entered into a Product Rights Agreement with Alimera Sciences, Inc. ("Alimera") to grant Alimera exclusive rights to develop, manufacture, sell, and commercialize YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg for the treatment of uveitis in the world excluding Europe, the Middle East, Africa, and specific Asian territories. Concurrently, EyePoint terminated its existing credit facilities with First Citizens BancShares, Inc. (successor to Silicon Valley Bank).
Key Financial Metrics and Transaction Terms
- Upfront Payment: $75 million received from Alimera.
- Guaranteed Payments: $7.5 million total, payable in four quarterly installments during 2024.
- Royalties: Low-to-mid double-digit percentage of Alimera's annual U.S. net sales of certain products (including YUTIQ) in excess of thresholds starting at $70 million in 2025, increasing annually through 2028.
- Debt Repayment: Full repayment of $30.0 million outstanding principal under the Term Facility.
- Transaction Fees: Approximately $1.49 million in total fees and accrued interest paid to the lender (including a $600,000 prepayment fee, $600,000 exit fee, $139,375 accrued interest, and $154,696 in other fees).
- Restructuring Costs: Estimated $1.2 million to $1.6 million in pre-tax charges and cash outlays for a reduction in force (RIF) of approximately 35 employees.
Material Changes Versus Prior Period
Asset Disposition and Licensing: EyePoint transferred the YUTIQ New Drug Application (NDA #210331) and related assets to Alimera. The Company will no longer directly commercialize YUTIQ in the Licensed Territory but will retain rights to other products, including EYP-1901.
Debt Elimination: The Company terminated its $30 million Term Facility and $15 million Revolving Facility, releasing all security interests and liens held by the lender.
Workforce Reduction: The Company committed to terminating approximately 35 employees, primarily within the sales and marketing organization, to align with the new strategic focus on its pipeline.
Supply Chain Shift: EyePoint entered a Commercial Supply Agreement to manufacture and exclusively supply YUTIQ to Alimera on a cost-plus basis for an initial 18-month term, after which Alimera may elect to manufacture the product.
Guidance, Outlook, and Risks
Liquidity Outlook: Management anticipates that existing cash, cash equivalents, marketable securities, the $75 million upfront payment, and the $7.5 million in guaranteed payments will fund operations into 2025. This projection assumes current expectations regarding the timing and outcomes of Phase 2 clinical trials for EYP-1901.
Strategic Focus: The Company intends to focus on advancing and expanding its pipeline of sustained delivery treatments for serious eye diseases, specifically highlighting EYP-1901.
Risks and Contingencies:
- Cash Runway: The estimate to fund operations into 2025 is based on assumptions that may prove incorrect; capital resources could be consumed sooner.
- Royalty Thresholds: Future royalty income is contingent on Alimera achieving specific sales thresholds.
- Restructuring Costs: Actual RIF costs may differ materially from the $1.2 million to $1.6 million estimate, particularly if Alimera hires impacted employees.
- Counterparty Risk: Risks include Alimera's ability to commercialize YUTIQ, potential breaches of the agreement, and the success of the technology transfer.
Investor Verification Checklist
- Verify the exact timing and receipt of the $75 million upfront payment and the schedule for the $7.5 million guaranteed payments.
- Confirm the specific sales thresholds and royalty percentages applicable to the 2025-2028 period in the full Product Rights Agreement.
- Monitor the actual costs incurred for the reduction in force (RIF) against the estimated $1.2 million to $1.6 million range in upcoming quarterly reports.
- Review the progress of the technology transfer for YUTIQ manufacturing to ensure the transition from EyePoint to Alimera occurs as scheduled.
- Assess the clinical trial timeline and results for EYP-1901, as this is the primary driver of the Company's future value post-transaction.